Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 2/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | PNP | P00491 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | EDNRA | P25101 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2400412 | 0.87 | TK1 (0.43) | TK1PNPKMT2AMEN1HSD17B10 | |
| SCHEMBL29286377 | 0.83 | TK1 (0.46) | TK1PNPKMT2AMEN1HSD17B10 | |
| SCHEMBL28712711 | 0.82 | PNP (0.42) | TK1PNPKMT2AMEN1HSD17B10 | |
| SCHEMBL4592790 | 0.81 | ADORA2A (0.47) | TK1PNPKMT2AMEN1HSD17B10 | |
| SCHEMBL1665132 | 0.81 | TK1 (0.47) | TK1PNPKMT2AMEN1HSD17B10 | |
| SCHEMBL11036998 | 0.81 | PNP (0.41) | TK1NPSR1PNPKMT2AMEN1 | |
| SCHEMBL20472443 | 0.80 | AKR1B1 (0.44) | TK1ADORA2BPNPHSD17B10ALDH1A1 | |
| SCHEMBL48223 | 0.78 | PNP (0.42) | TK1ADORA2BPNPKMT2AMEN1 | |
| SCHEMBL27710751 | 0.78 | ADORA2A (0.52) | TK1ADORA2BKMT2AMEN1ALDH1A1 | |
| SCHEMBL48362 | 0.78 | TK1 (0.51) | TK1ADORA2BPNPKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1679 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013071079-A1 | LIN28/LET-7 CRYSTAL STRUCTURES, PURIFICATION PROTOCOLS, AND MOLECULAR PROBES SUITABLE FOR SCREENING ASSAYS AND THERAPEUTICS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-05-16 | — | — | WO | claimed |
| US-20250034143-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, LLC (US) | 2025-01-30 | — | — | US | disclosed |
| US-12042541-B2 | Lipids and compositions for the delivery of therapeutics | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-23 | — | — | US | disclosed |
| US-12043637-B2 | Fluorescent dyes containing bis-boron fused heterocycles and uses in sequencing | ILLUMINA CAMBRIDGE LIMITED (GB) | 2024-07-23 | — | — | US | disclosed |
| WO-2024151673-A2 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151685-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240240217-A1 | NUCLEOSIDES AND NUCLEOTIDES WITH 3' BLOCKING GROUPS AND CLEAVABLE LINKERS | ILLUMINA, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-18 | — | — | US | disclosed |
| WO-2024151687-A1 | GENETIC SWITCHES AND THEIR USE IN TREATING CANCER | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240238473-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-07-18 | — | — | US | disclosed |
| WO-2004094595-A2 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004091515-A2 | iRNA CONJUGATES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004090108-A2 | IRNA CONJUGATES | ALNYLAM PHARMACEUTICALS (US) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004080406-A2 | THERAPEUTIC COMPOSITIONS | ALNYLAM PHARMACEUTICALS (US) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004064737-A2 | THERAPEUTICS COMPOSITIONS | ALNYLAM PHARMACEUTICALS (US) | 2004-08-05 | — | — | WO | disclosed |
| US-20040137456-A1 | Forming abasic sites specific for at least one nucleic acid base, labeling said abasic sites, then detecting the location of the labeled molecules; atomic force microscopy; diagnosing genetic disorders; detecting bacteria or viruses; paternity | ADVANCED RESEARCH & TECHNOLOGY INSTITUTE, INC. | 2004-07-15 | — | — | US | disclosed |
| WO-2002081753-A1 | METHOD FOR IDENTIFYING AND CHARACTERIZING INDIVIDUAL DNA MOLECULES | ADVANCED RESEARCH & TECHNOLOGY INSTITUTE (US) | 2002-10-17 | — | — | WO | disclosed |
| US-6252048-B1 | FUSION PROTEIN FOR THE TREATMENT AND PREVENTION OF CANCER | ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE | 2001-06-26 | — | — | US | disclosed |
| US-6046036-A | FOR INCREASING SURVIVAL RATE OF NON-TARGET CELLS SUCH AS HEMATOPOIETIC CELLS WHEN CONTACTED WITH ANTICARCINOGENIC/DNA-DAMAGING AGENTS DURING MULTIAGENT CHEMOTHERAPY PROTOCOLS OR IN FANCONI'S ANEMIA | ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE (US) | 2000-04-04 | — | — | US | disclosed |
| WO-1998017684-A2 | DNA SEQUENCES ENCODING FUSIONS OF DNA REPAIR PROTEINS AND USES THEREOF | ADVANCED RESEARCH & TECHNOLOGY INSTITUTE (US) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12043637-B2 | Fluorescent dyes containing bis-boron fused heterocycles and uses in sequencing | BLVRB, BCDIN3D, FOSB | TK1 202/4885ADORA2B 954/4885NPSR1 2274/4885 |
| US-20240240217-A1 | NUCLEOSIDES AND NUCLEOTIDES WITH 3' BLOCKING GROUPS AND CLEAVABLE LINKERS | NT5C2, DUT, NT5C3B | TK1 22/4885ADORA2B 296/4885NPSR1 1579/4885 |
| US-20240238473-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | CHI3L2, CHI3L1, FGF2 | TK1 331/4885ADORA2B 3837/4885NPSR1 3388/4885 |
| US-12042541-B2 | Lipids and compositions for the delivery of therapeutics | PHOSPHO1, MBOAT1, SGMS1 | TK1 470/4885ADORA2B 1519/4885NPSR1 1892/4885 |
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC47A1, TMEM205 | TK1 1852/4885ADORA2B 1915/4885NPSR1 1123/4885 |
| US-20250034143-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | TK1 1268/4885ADORA2B 577/4885NPSR1 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.